Homepage Top Section2

Mirum Pharmaceuticals is focused on the development of an approach for treating cholestatic liver diseases, with an immediate focus on rare pediatric conditions. Maralixibat is under development for

Lorbrena is a third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) to treat patients with ALK-positive metastatic NSCLC whose disease has progressed on crizotinib and at least

The approval paves way for the use of Hyrimoz in the treatment of rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA) in patients four years of age and older,

For Nexium, which is used in the treatment of gastroesophageal reflux disease, ulcers, and Zollinger-Ellison syndrome, Grünenthal will be acquiring the prescription medicine rights in Europe, which will

Karo Pharma develops and markets products for pharmacies and also directly to the healthcare sector. The specialty pharma company is said to have a strong presence in the

The 52-week, randomized, double-blind, placebo-controlled study investigated the LDL-C lowering efficacy and the safety and tolerability of bempedoic acid 180mg in comparison to placebo. It was carried out

The regulator issued a complete response letter (CRL) over the chemistry, manufacturing and controls (CMC) prior-approval supplement (PAS) for the Eylea pre-filled syringe. Eylea injection is a vascular

Xofluza is a first-in-class and single-dose oral medicine with a novel proposed mechanism of action, which restricts polymerase acidic endonuclease, an enzyme required for viral replication. According to

Ci:z is engaged in the development, marketing and distribution of a range of dermocosmetic, cosmetic and skincare products. As per terms of the deal, J&J and its affiliates